References
- LiuGGouldALComparison of alternative strategies for analysis of longitudinal trials with dropoutsJ Biopharm Stat200212220722612413241
- LanePHandling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approachesPharm Stat2008729310617351897
- MallinckrodtCHSangerTMDubéSAssessing and interpreting treatment effects in longitudinal clinical trials with missing dataBiol Psychiatry200353875476012706959
- MallinckrodtCHLanePWSchnellDPengYMancusoJPRecommendations for the primary analysis of continuous endpoints in longitudinal clinical trialsDrug Inf J2008424303319
- ShaoJJordanDCPritchettYLBaseline observation carry forward: reasoning, properties, and practical issuesJ Biopharm Stat2009194672684
- SkljarevskiVDesaiahDLiu-SeifertHEfficacy and safety of duloxetine in patients with chronic low back painSpine2009In press
- ChappellASDesaiahDLiu-SeifertHDuloxetine 60 to 120 mg once daily versus placebo in the treatment of patients with osteoarthritis knee pain[Poster] Presented at the American Academy of Pain Medicine (AAPM) – 25th Annual MeetingHonolulu, HI, USAJan 28–31, 2009
- DworkinRHTurkDCWyrwichKWInterpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendationsJ Pain20089210512118055266
- AndersenJWVan Der HorstCGorskiHFassRJConference on Retroviruses and Opportunistic Infections. The association of site with early study discontinuation on HIV clinical studies in the protease inhibitor era: DACS200Program Abstr 8th Conf Retrovir Oppor Infect Conf Retrovir Oppor Infect 8th 2001 Chic Ill2001 Feb 4–88188 (abstract no. 486)
- AndersonJWFassRvan der HorstCFactors associated with early study discontinuation in AACTG studies, DACS 200Contemp Clin Trials200728558359217395549